View in EDS

Targeting Tumor Markers with Antisense Peptides: An Example of Human Prostate Specific Antigen

Saved in:
Bibliographic Details
Title: Targeting Tumor Markers with Antisense Peptides: An Example of Human Prostate Specific Antigen
Authors: Petra Turčić, Mario Gabričević, Hrvoje Šošić, Gorana Aralica, Piotr Wardega, Ana Gudelj Gračanin, Renata Novak Kujundžić, Željko Kaštelan, Damir Babić, Paško Konjevoda, Jelena Barać Žutelija, Nikola Štambuk, Sven Seiwerth
Source: Int J Mol Sci
International Journal of Molecular Sciences
Volume 20
Issue 9
Publisher Information: MDPI AG, 2019.
Publication Year: 2019
Subject Terms: Male, 0301 basic medicine, Nanomedicine / methods, Prostate-Specific Antigen / immunology, Prostatic Neoplasms / immunology, prostate specific antigen, Article, Protein Structure, Secondary, neoplasm, biomarker, antisense peptide, immunohistochemistry, nanomedicine, 03 medical and health sciences, Peptides / immunology, Biomarkers, Tumor, Humans, 0303 health sciences, Prostatic Neoplasms, Prostate-Specific Antigen, Immunohistochemistry, Biomarkers, Tumor / immunology, 3. Good health, Interdisciplinary Natural Sciences, Nanomedicine, Peptides
Description: The purpose of this paper was to outline the development of short peptide targeting of the human prostate specific antigen (hPSA), and to evaluate its effectiveness in staining PSA in human prostate cancer tissue. The targeting of the hPSA antigen by means of antisense peptide AVRDKVG was designed according to a three-step method involving: 1. The selection of the molecular target (hPSA epitope), 2. the modeling of an antisense peptide (paratope) based on the epitope sequence, and 3. the spectroscopic evaluation of sense–antisense peptide binding. We then modified standard hPSA immunohistochemical staining practice by using a biotinylated antisense peptide instead of the standard monoclonal antibody and compared the results of both procedures. Immunochemical testing on human tissue showed the applicability of the antisense peptide technology to human molecular targets. This methodology represents a new approach to deriving peptide ligands and potential lead compounds for the development of novel diagnostic substances, biopharmaceuticals and vaccines.
Document Type: Article
Other literature type
File Description: application/pdf
Language: English
ISSN: 1422-0067
DOI: 10.3390/ijms20092090
Access URL: https://www.mdpi.com/1422-0067/20/9/2090/pdf
https://pubmed.ncbi.nlm.nih.gov/31035335
https://www.bib.irb.hr/1010802
https://doi.org/10.3390/ijms20092090
https://europepmc.org/articles/PMC6540241
https://www.bib.irb.hr/1010802
https://pubmed.ncbi.nlm.nih.gov/31035335/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6540241
http://fulir.irb.hr/4862/
https://www.mdpi.com/1422-0067/20/9/2090/htm
http://fulir.irb.hr/4862/1/StambukN_TargetingTumorMarkersIJMS_20_2019_02090.pdf
https://urn.nsk.hr/urn:nbn:hr:105:903196
https://doi.org/10.3390/ijms20092090
http://doi.org/10.3390/ijms20092090
Rights: CC BY
URL: http://rightsstatements.org/vocab/InC/1.0/
Accession Number: edsair.doi.dedup.....9e9e5cd6f4bd651480be0dec8edf6eb0
Database: OpenAIRE
Description
Abstract:The purpose of this paper was to outline the development of short peptide targeting of the human prostate specific antigen (hPSA), and to evaluate its effectiveness in staining PSA in human prostate cancer tissue. The targeting of the hPSA antigen by means of antisense peptide AVRDKVG was designed according to a three-step method involving: 1. The selection of the molecular target (hPSA epitope), 2. the modeling of an antisense peptide (paratope) based on the epitope sequence, and 3. the spectroscopic evaluation of sense–antisense peptide binding. We then modified standard hPSA immunohistochemical staining practice by using a biotinylated antisense peptide instead of the standard monoclonal antibody and compared the results of both procedures. Immunochemical testing on human tissue showed the applicability of the antisense peptide technology to human molecular targets. This methodology represents a new approach to deriving peptide ligands and potential lead compounds for the development of novel diagnostic substances, biopharmaceuticals and vaccines.
ISSN:14220067
DOI:10.3390/ijms20092090